文献速递垂体与肾上腺疾病

123I-MIBG闪烁显像对嗜铬细胞瘤和副神经节瘤临床决策的影响

Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该国际多中心回顾性研究纳入单侧肾上腺、双侧肾上腺、单灶肾上腺外、多灶及转移性嗜铬细胞瘤和副神经节瘤患者,比较单独CT/MRI与CT/MRI联合123I-MIBG闪烁显像的诊断准确性及对治疗决策的影响。结果显示联合显像并未提高诊断正确率(89.4% vs 88.8%,P=0.50),仅少数病例改变诊断和治疗,但错误改变更多,提示123I-MIBG对临床决策影响有限。

要点

  • 在CT/MRI基础上加做123I-MIBG闪烁显像未显著提高嗜铬细胞瘤和副神经节瘤的诊断准确率。
  • 联合显像仅使1.2%的病例诊断和治疗正确改变,却导致2.1%的病例错误改变。
  • 即使限于转移风险患者,123I-MIBG对临床决策的影响仍很小。

核心结论

  • 在嗜铬细胞瘤和副神经节瘤的初始定位中,将123I-MIBG闪烁显像加入CT/MRI很少提高诊断准确性,反而在部分患者中导致错误解读,对临床决策影响非常有限。

研究设计与样本

  • 所有患者均接受解剖成像(CT和/或MRI)及123I-MIBG闪烁显像,图像由两名不知诊断的独立观察者集中分析。

主要发现

  • 单独CT/MRI与CT/MRI联合123I-MIBG闪烁显像的正确诊断率相似:89.4% vs 88.8%(P=0.50)。
  • 联合显像导致4例(1.2%)诊断和治疗正确改变:2例转移改为非转移、1例多灶改为单灶、1例单侧肾上腺改为双侧肾上腺。
  • 联合显像导致7例(2.1%)诊断和治疗错误改变:4例非转移改为转移、2例单灶改为多灶、1例双侧肾上腺改为单侧肾上腺。

临床怎么用

  • 对于嗜铬细胞瘤和副神经节瘤的初始定位,CT或MRI仍是首选影像学方法。
  • 不推荐常规将123I-MIBG闪烁显像加入CT/MRI以改善诊断准确性或治疗决策。

局限性

  • 本研究为回顾性设计,结果基于虚拟治疗影响分析,非真实临床决策。
  • 图像分析为集中盲法阅片,可能不同于实际临床场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. OBJECTIVE: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. DESIGN: International multicenter retrospective study. INTERVENTION: None. PATIENTS: Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. MAIN OUTCOME MEASURES: Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. RESULTS: The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). CONCLUSIONS: For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rao D, van Berkel A, Piscaer I, et al. Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2019. PMID: 30822354. doi:10.1210/jc.2018-02355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。